294 reports of this reaction
2.5% of all BARICITINIB reports
#5 most reported adverse reaction
PULMONARY EMBOLISM is the #5 most commonly reported adverse reaction for BARICITINIB, manufactured by Eli Lilly and Company. There are 294 FDA adverse event reports linking BARICITINIB to PULMONARY EMBOLISM. This represents approximately 2.5% of all 11,538 adverse event reports for this drug.
Patients taking BARICITINIB who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for BARICITINIB, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for BARICITINIB:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 294 FDA reports for BARICITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 2.5% of all adverse event reports for BARICITINIB, making it a notable side effect.
If you experience pulmonary embolism while taking BARICITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.